• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

DOBI Medical International Announces Fall 2005 Scientific and Investment Conference Participation Schedule

Posted on: Tuesday, 6 September 2005, 18:01 CDT

DOBI Medical International, Inc. (DBMI.OB) announced today the schedule of scientific and investment industry conferences at which the company plans to participate for the balance of 2005. These events are part of the Company's ongoing program to raise awareness and strengthen partnerships among members of the investment, scientific and medical communities as the company continues the data collection process for its PMA clinical study.

The Company will participate in prominent scientific conferences including the Radiological Society of North America (RSNA) 91st Scientific Assembly and Annual Meeting, the 3rd Annual Antiangiogenesis Symposium, and the 28th Annual San Antonio Breast Cancer Symposium. DOBI Medical will exhibit its ComfortScan(R) system, designed to identify tumor angiogenesis, a key element in cancer progression. Medical and scientific conferences in which the Company will participate are listed below. Medical and Scientific Conferences September 9-11: Prague, Czech Republic DOBI Medical International 2nd Annual European Symposium in Optical Breast Imaging William W. Li, MD, The Angiogenesis Foundation (keynote address) October 20-21: Boston, MA 3rd Annual Antiangiogenesis Symposium: New Frontiers in Therapeutic Development Hilton Boston Back Bay Judah Folkman, MD, Harvard Medical School (keynote address) Phillip C. Thomas, CEO, DOBI Medical (presenter) October 25-28: Shanghai, China China-Pharm/CISO 2005 - 10th China International Pharmaceutical Industry Exhibition Shanghai New International Expo Centre, booth #A100 November 27-December 1: Chicago, IL RSNA 2005 - 91st Scientific Assembly and Annual Meeting McCormick Place, booth #8361 (abstract accepted) November 28-December 2: Moscow, Russia 15th ZDRAVOOKHRANENIYE'2005 International Exhibition ZAO Expocentr December 8-10: San Antonio, TX 28th Annual San Antonio Breast Cancer Symposium Henry B. Gonzalez Convention Center

DOBI Medical will also present at and participate in financial conferences including the Value Rich Small Cap Expo taking place at the Javits Center in New York City September 14 and 15, the CE Unterberg Towbin Healthcare Conference October 25-26, as well as the Rodman & Renshaw Techvest 7th Annual Healthcare Conference taking place in New York November 7-9. More than 4,000 financial professionals are expected to attend these three events.

Investment Conferences: September 14-15: New York, NY ValueRich - Small-cap Financial Expo Javits Center, booth #169 October 25-26: New York, NY CE Unterberg Towbin Healthcare Conference The New York Palace Hotel November 7-9: New York, NY Rodman & Renshaw Techvest 7th Annual Healthcare Conference The New York Palace Hotel

About DOBI Medical International, Inc.

DOBI Medical is a microcap, developmental stage, medical imaging company working to create a new means for the improved diagnosis of cancer through the detection of abnormal neovascularization ("angiogenesis") associated with tumors. DOBI Medical International's first application of the technology is the ComfortScan system, a gentle, noninvasive, and non-ionizing, optical imaging system designed as an adjunct to mammography to assist physicians in the detection and management of breast cancer. The ComfortScan system is intended to achieve this by providing new, physiology-based imagery of abnormal vascularization in the breast that is not readily available today. The ComfortScan system has CE Mark and UL certifications. DOBI Medical is a certified ISO 9001:2000 and ISO 13485:2003 company. The Company currently sells its ComfortScan systems to international distributors for installation at international clinical trial sites. The ComfortScan system is not being sold in the U.S. as it is limited by U.S. law to investigational use until approved by the FDA, which cannot be guaranteed. For more information on DOBI Medical International or the ComfortScan(R) system, visit www.dobimedical.com.

CAUTIONARY STATEMENT FOR FORWARD-LOOKING STATEMENTS

Statements in this press release contain information that includes or is based upon certain "forward-looking statements" relating to our business. These forward-looking statements represent management's current judgments and assumptions as of the date of this report Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts, and are frequently accompanied by the use of such words as "may", "will", "anticipates,""plans,""believes,""expects,""projects,""intends,""seeks", "anticipates", and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors, including without limitation, successful verification and validation for release of our ComfortScan 2.0 system; those relating to our ability to timely and successfully complete our patient clinical trials; our ability to timely and successfully complete and submit our premarket approval application to the FDA; the timely and final approval by the FDA of our ComfortScan system as a adjunct to mammography, which approval in the U.S. cannot be assured; the submission and final approval of our ComfortScan system in various international markets, which approval cannot be assured; the success and continued improvements in our product development and research efforts; our ability to timely meet U. S. and foreign government laws and industry standards; our ability to meet U.S. and foreign medical device quality regulation standards required to maintain our CE Mark, and to maintain our ISO, UL and FDA Export certifications; our ability to timely and successfully ship and deliver our products into international markets; the acceptance and use of our ComfortScan system by physicians, hospitals, imaging clinics, and patients; and our ability to obtain adequate third party coverage, coding and reimbursement from U.S. and foreign government and private payers.

We caution readers not to place undue reliance on forward-looking statements, which speak only as of the date of this report. Any one of these or other risks, uncertainties, other factors or any inaccurate judgments and assumptions could cause actual results to be materially different from those described herein or elsewhere by us. Certain of these risks, uncertainties, and other factors are described in greater detail in our filings from time to time with the Securities and Exchange Commission, which we strongly urge you to read and consider, including the "Investment Considerations" and the "Cautionary Factors That May Affect Future Results" as set forth in our 2004 Annual Report on Form 10-KSB, as amended, and the "Risk Factors" in our Registration Statement on Form SB-2 declared effective on May 11, 2005, our 2005 Second Quarter Report on Form 10-QSB, and our Current Reports on Form 8-K, all of which may be accessed from our website at www.dobimedical.com. Subsequent written and oral forward-looking statements attributable to us or to persons acting on our behalf are expressly qualified in their entirety by the cautionary statements set forth above and elsewhere in our reports filed with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Source: Business Wire

More News in this Category